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UGT1A expression is required to maintain and sustain p53
activation in stress-induced colon epithelial cells, and it has
a signiﬁcant impact on p53-mediated apoptosis and tumor
suppression.
BACKGROUND & AIMS: The UDP-glucuronosyltransferases
(UGTs) are a part of the cell machinery that protects the tis-
sues from a toxicant insult by environmental and host cell
metabolites. We investigated the mechanism behind tumor
growth and UGT repression.
METHODS: We initially silenced the Ugt1 locus in human
colon cell lines and investigated markers and responses
linked to p53 activation. To examine the role of the Ugt1 locus
in p53-directed apoptosis and tumorigenesis, experiments
were conducted to induce acute colon inﬂammation and
chemically induced colon cancer in mice where we have
selectively deleted the Ugt1 locus in the intestinal epithelial
cells (Ugt1DIEC mice).
RESULTS: Knockdown of the UGT1A proteins by RNAi in
human colon cancer cells and knockout of the Ugt1 locus in
intestinal crypt stem cells reduces phosphorylated p53 acti-
vation and compromises the ability of p53 to control
apoptosis. Targeted deletion of intestinal Ugt1 expression in
Ugt1DIEC mice represses colon inﬂammation-induced p53
production and proapoptotic protein activation. When we
induced colon cancer, the size and number of the tumors
were signiﬁcantly greater in the Ugt1DIEC mice when
compared with wild-type mice. Furthermore, analysis of
endoplasmic reticulum (ER) stress-related markers indicated
that lack of UGT1A expression causes higher ER stress in
intestinal epithelial cells and tissue, which may account for
the lower expression of p53.
CONCLUSIONS: Our results demonstrate that UGT1A expres-
sion is required to maintain and sustain p53 activation in
stress-induced colon epithelial cells and has a signiﬁcant impact
on p53-mediated apoptosis and tumor suppression, thus pro-
tecting the colon tissue from neoplastic transformation. (Cell
Mol Gastroenterol Hepatol 2016;2:63–76; http://dx.doi.org/
10.1016/j.jcmgh.2015.08.008)
Keywords: Apoptosis; Colon Cancer; ER Stress; UGT1A.olorectal cancer (CRC) ranks as the third mostCcommon cancer worldwide and the second leading
cause of cancer-related deaths in Western society.1,2 The
majority of colorectal tumors are epithelial tumors, whereas
lymphomas, endocrine tumors, and mesenchymal tumors
are quite uncommon.3 As an important extrahepatic tissue
of xenobiotic metabolism, the colorectum is in direct contact
with xenobiotic substances, including potentially toxic or
carcinogenic agents, presumably leading to the high inci-
dence rate of CRC.4,5 By contrast, cancers of the small in-
testine are rarely seen, even though the small intestine has a
larger mucosal surface area than the colorectum.6 One
plausible explanation is that expression of biotransforma-
tion enzymes, including glutathione S-transferases, UDP-
glucuronosyltransferases (UGT), and cytochrome P450, are
lower in the colorectum than in the small intestine. These
enzymes are responsible for the detoxiﬁcation of ingested
toxins, carcinogens, or tumor-promoting compounds, and
their lower expression levels in colorectum are considered
to be a contributing factor to the high rate of CRC.7,8
As an important part of the detoxiﬁcation process, glu-
curonidation provides an effective metabolic process lead-
ing toward the biological inactivation of potential toxicants
and carcinogens. Previous studies have demonstrated that
gastrointestinal UGT activity decreases sharply from the
small intestines to the colon tissue.7 This decrease in UGT
activity contributes to higher colonic DNA damage caused
by carcinogens, such as heterocyclic amines and polycyclic
aromatic hydrocarbons, which are usually detoxiﬁed
through UGT glucuronidation.9–11 It has been speculated
that glucuronidation provides a genoprotective defense
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Studies have found that UGT expression in colorectal tumor
tissues is signiﬁcantly reduced in comparison to surround-
ing healthy tissues.12–14 Indeed, the pattern of UGT down-
regulation is also identiﬁed in other types of cancer,
including liver and biliary cancer,15 breast cancer,16 and
bladder cancer.17 These ﬁndings indicate that UGT expres-
sion is reversely correlated with tissue neoplastic trans-
formation. However, there is no evidence that the UGTs
impact the outcome of tumorigenesis, and the underlying
mechanism regarding the role of the UGTs in cancer
development is largely unexplored.
Recent studies have shown a link between the UGTs
and p53, an important regulator of cell cycle, apoptosis,
and tumorigenesis. Ariyoshi et al18 observed increased
constitutive UGT1A activity in p53þ/ mice, and Hu et al19
veriﬁed that epirubicin up-regulates UGT2B7 expression
via a p53 pathway. In contrast to these studies, our initial
discovery uncovered an opposite causal relationship be-
tween UGT1A and p53 when we challenged cells with
chemical stress. Cell apoptotic death is a well-deﬁned
mechanism that is associated with cancer suppression
when the body encounters tumor-promoting challenges.
P53 and its signaling network are known to play a critical
role in the regulation of the cell cycle and apoptosis to
conserve gene stability, thus suppressing tumor develop-
ment.20,21 Upon occurrence of cellular stress, such as
oncogene activation or DNA damage, p53 is activated.
When cell damage is minimal, p53 evokes cell cycle arrest
by inducing p21 to promote DNA repair and cell survival,
whereas sustained p53 activation in response to high
damage levels triggers cellular apoptosis, thus preventing
the expansion of damaged cells and protecting normal
tissue from neoplastic transformation.22,23 This is evi-
denced by the fact that the development of certain tumors
in p53 null mice has been associated with decreased
apoptosis, implying the important role of p53 in promoting
cell death during tumor suppression.24
Our study explored the role of the UGT1A proteins in CRC
by using colon cancer cell lines and an intestinal conditional
knockout animal model deﬁcient in Ugt1 locus expression.
By documenting molecular and cellular events that are
associated with p53-dependent signaling, this study sheds
light on the importance of UGT1A expression on p53-
dependent stress responses and tumor suppression.Materials and Methods
Chemicals and reagents
Actinomycin D, etoposide, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), and azoxymethane
(AOM) were purchased from Sigma-Aldrich (St. Louis, MO),
and dextran sulfate sodium (DSS, molecular weight
36,000–50,000) was obtained from MP Biomedicals (Santa
Ana, CA). The quantitative real-time polymerase chain
reaction (qRT-PCR) primers were commercially synthesized
from Integrated DNA Technologies (San Diego, CA).
Antibodies against UGT1A (Abcam, Cambridge, MA),
p21 (Chemicon, Temecula, CA), p53 and Bax (Santa CruzBiotechnology, Dallas, TX), and caspase-9 and caspase-3
(Cell Signaling Technology, Beverly, MA) were used in
Western blot analyses.Cell Culture and UGT1A Silencing
The human colon epithelial cell lines HT29 and LS180
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). For UGT1A gene silencing, two pairs
of UGT1A-speciﬁc small interfering RNA (siRNA) designed
along with nonspeciﬁc siRNA as a negative control were
used. The siRNA (Invitrogen/Life Technologies, Carlsbad,
CA) was mixed with the Lipofectamine RNAiMAX Reagent
(Invitrogen) in Opti-MEM I medium (GIBCO/Life Technolo-
gies, Grand Island, NY) at a ﬁnial concentration of 30 nM
and was incubated at room temperature for 10 minutes
according to the manufacturer’s instructions. The mixture
was added to culture plates, and exponentially growing cells
were then seeded in these plates. Cells were incubated for
24–72 hours until further analyses.Mouse Crypt Cell Preparations and Culture
Crypt cell isolation and culture were performed as
previously described elsewhere.25 Intestines from adult
Ugt1F/F and Ugt1DIEC mice were dissected, opened longi-
tudinally, and gently washed with ice-cold phosphate-
buffered saline (PBS) buffer. Intestinal tissue was then
incubated in PBS buffer containing 2 mM EDTA at 4C for
30 minutes. The buffer was removed, and the tissue was
shaken vigorously and then ﬁltered through a 70-mm cell
strainer. The ﬁltrate was centrifuged at 1000g for 10 mi-
nutes to precipitate the crypt cells, followed by a wash with
Advanced Dulbecco’s modiﬁed Eagle medium/Ham’s F-12
medium (Life Technologies, Carlsbad, CA). The cells were
counted, and approximately 1000 crypts were suspended
into 50 mL of Matrigel (BD Biosciences, San Jose, CA), and
the cells plated into 24-well plates. After 10 minutes, 500
mL of crypt culture medium Advanced Dulbecco’s modiﬁed
Eagle medium/Ham’s F-12 supplemented with B27 (Life
Technologies), N2 (Life Technologies), 1 mM N-acetyl
cysteine (Sigma-Aldrich), 100 ng/mL mNoggin and R-
spondin 1 (conditioned medium, R-spondin 1 expression
293-HA-Rspol-Fc cell line was a generous gift from Dr.
Calvin Kuo, University of Stanford) were added. Growth
factors were added every other day, and the medium was
changed every 4 days. Cells were passaged every 1 to 2
weeks.Cytotoxicity Assay
Cells were seeded at 7000 cells per well to a 96-well
plate and incubated overnight. The cells were subse-
quently exposed to the indicated concentrations of actino-
mycin D or etoposide. After 36 hours, the MTT solution was
added to each well at a ﬁnal concentration of 0.5 mg/mL,
and the plate was incubated at 37C for another 4 hours.
The MTT solution was then removed and 150 mL of DMSO
per well was added. The absorbance at 595 nm was
measured by a microplate reader.
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The HT29 cells were exposed to the indicated concen-
tration of actinomycin D or etoposide for 36 hours and then
harvested by 0.25% trypsin without EDTA. The ﬂuorescein
isothiocyanate (FITC) Annexin V Apoptosis Detection Kit
(BioLegend, San Diego, CA) was used to stain the cells.
Samples were analyzed using a ﬂow cytometer (BD FACS-
Calibur; BD Biosciences).
Ugt1 Conditional Knockout Mouse Lines
Mice carrying loxP recombinase sites positioned in
Ugt1a1 intron 2 and intron 4 (Ugt1F/F mice) were previously
generated.14 When the mice were bred with villin-Cre mice,
Cre-mediated recombination resulted in the deletion of
exons 3 and 4 in the common region of the Ugt1a locus
speciﬁcally in intestinal epithelial cells (Ugt1DIEC mice),
leading to knockout of the entire Ugt1 locus.
Animal Treatment With Dextran Sodium Sulfate
or Azoxymethane Plus Dextran Sodium Sulfate
For the acute colitis experiment, 8- to 10-week-old
Ugt1F/F or Ugt1DIEC mice were treated with 3% DSS in
drinking water for 5 days, followed by 5 days of regular
water. The mice were sacriﬁced, and the colons were
removed, rinsed with PBS, and cut lengthwise into two
segments. One segment was put into liquid nitrogen
immediately and then stored at 80C for subsequent
analysis; the other segment was ﬁxed as “Swiss rolls” in
10% formalin at 4C overnight and stored in 75% alcohol
for parafﬁn embedding.
For the tumorigenesis study, 8- to 10-week-old Ugt1F/F
or Ugt1DIEC mice were intraperitoneally injected with 10
mg/kg AOM. After 5 days, 2% DSS was provided in the
drinking water for 5 days, followed by 16 days of regular
water. The cycle of DSS water followed by regular water was
repeated twice. Mice were sacriﬁced 7 days after the last
cycle; their colons were removed, analyzed for the presence
of tumors (number counted and size measured), and pre-
pared according to the previous description.
TUNEL Analysis
Parafﬁn-embedded tissues were sectioned (5 mm) and
analyzed with terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) staining, a common method for
detecting DNA fragmentation resulting from apoptosis, by
using the in situ cell death detection kit (Roche Applied
Science, Indianapolis, IN). Counterstaining with 40,6-
diamidino-2-phenylindole (DAPI) was performed before
the slides were mounted, and they were observed under a
Leica ﬂuorescence microscope (Leica Microsystems GmbH,
Wetzlar, Germany).
Western Blot Analysis
All Western blots were performed by using NuPAGE
BisTris-polyacrylamide gels (Invitrogen) with the protocols
described by the manufacturer. Membranes were blocked
with 5% skim milk and incubated with speciﬁc primaryantibodies at 4C overnight. Subsequently, the membranes
were incubated with horseradish peroxidase-conjugated
secondary antibody for 1 hour at room temperature. Blots
were developed by a Western Lightning Plus-ECL agent
(PerkinElmer Life and Analytical Sciences, Waltham, MA)
and were visualized under the Bio-Rad gel documentation
system.
Total RNA Preparation and Gene Expression
Analysis by Q-PCR
The colon sample was homogenized in 1 mL of TRIzol
(Invitrogen), and the total RNA was extracted and used to
generate cDNA with the iScript cDNA Synthesis Kit (Bio-Rad
Laboratories). After cDNA synthesis, RT-PCR was performed
with the Soadvanced SYBR Green Supermix (Bio-Rad Lab-
oratories) using a CFX96 Touch Real-Time PCR detection
system (Bio-Rad Laboratories). The sequences of the
primers used are listed in Supplementary Table 1.
Statistical Analysis
All data were obtained by at least three independent
experiments and are presented as mean ± standard de-
viation. Statistical differences between two treatment
groups were evaluated using the Student’s t test. When
comparing induction responses between two groups,
two-way analysis of variance (ANOVA) was performed
followed by Bonferroni post-tests. P < .05 was considered
statistically signiﬁcant, and statistically signiﬁcant
differences are indicated with asterisks (*P < .05;
**P < .01; ***P < .001).
Results
UGT1A Knockdown by siRNA Silencing
and p53 Expression
To explore the role of the UGT1A proteins in p53-
dependent signaling, the UGT1A genes were silenced by
UGT1A siRNA transfections in HT29 and LS180 colon cancer
cell lines (Figure 1A and Supplementary Figure 1). When the
cells were treated with anticancer drugs actinomycin D and
etoposide, which are known to induce p53,26,27 both acti-
nomycin D and etoposide induced p53 total protein
expression in a dose-dependent fashion (see Figure 1B and C,
and Supplementary Figure 1). This treatment led to spon-
taneous increases in p21 and Bax, both of which are well-
deﬁned p53 downstream target genes, along with in-
creases in apoptosis markers caspase-9 and caspase-3 (see
Figure 1B and C). Loss of UGT1A gene expression led to a
statistically signiﬁcant decrease in actinomycin D- and
etoposide-induced p53 expression in both HT29 and LS180
colon epithelial cells. Consequently, actinomycin D- and
etoposide-mediated induction of p21 and Bax and apoptosis
biomarkers caspase-9 and caspase-3 was also inhibited by
UGT1A silencing, indicating the requirement of UGT1A
protein expression for p53 elevation and p53-dependent
target gene induction.
The MTT cell proliferation assay measures total
mitochondrial activity, which is a measurement of
Figure 1. UGT1A silencing




ptosis pathway in LS180
and HT29 colon epithelial
cells. (A) Assessment of
gene-silencing efﬁciency
for the two pairs of UGT1A
siRNAs (siRNA1, siRNA2).
Cells were treated with
UGT1A-speciﬁc siRNA or
nonspeciﬁc siRNA for 48
hours, and protein expres-
sion levels were examined
by Western blot analysis.
The cell sample without
any treatment was indi-
cated as “none” and
treated with nonspeciﬁc
siRNA was indicated as
“control.” (B) Protein ex-
pression of p53 and genes
regulated by p53. LS180




48 hours and then incu-
bated with actinomycin D
(ActD, 20, 40, 80 nM) or
etoposide (Eto, 40, 80 160
mM) for 36 hours. Whole
cell lysates were prepared
and expression of UGT1A,
p53, p21, Bax, cleaved
caspases-9, and cleaved
caspases-3 were exam-
ined by Western blots.
These represent an
example taken from 3 in-
dependent experiments,
where combined expres-
sion levels are quanti-
tated in Supplementary
Figures 1A and 1B.
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detects cell viability but cannot distinguish between
apoptosis and proliferation, although proliferation is a
common reference for this assay. We observed that
actinomycin D and etoposide treatments blocked
mitochondrial dehydrogenase activity (relative absor-
bance) in a dose-dependent manner in both HT29
and LS180 cells, indicating that these agents are
apoptotic or antiproliferative. By comparison, knock-
down of UGT1A proteins in these cell lines reduced theantiproliferative/apoptotic effects elicited by actino-
mycin D and etoposide (Figure 2A).
We further detected the impact of chemical treatment on
apoptosis by using annexin V-ﬂuorescein isothiocyanate/
propidium iodide staining, and the results show signiﬁcantly
fewer apoptotic cells in HT29 cells lacking UGT1A protein
expression (see Figure 2B). Collectively, these results
demonstrate that interruption of UGT1A protein expression
inﬂuences the regulation of p53 and p53-dependent cell
cycle arrest and cell death signaling.
Figure 2. UGT1A silencing lowers the antiproliferative activity of actinomycin D and etoposide in both HT29 and LS180
cells. Cells were pretreated with UGT1A siRNA1 or nonspeciﬁc siRNA for 24 hours and then exposed to gradient concen-
trations of actinomycin D or etoposide for 36 hours. (A) Cell proliferation was measured by MTT assay in actinomycin- or
etoposide-treated LS180 and HT29 cells. The proliferation rate of cells is expressed as Relative Absorbance (mitochondrial
dehydrogenase activity) with non-speciﬁc siRNA is expressed as 1. (B) Annexin V ﬂuorescein isothiocyanate/propidium iodide
staining of HT29 cells was examined by a ﬂow cytometer. Results are presented as mean ± standard deviation of at least four
independent experiments (*P < .05, **P < .01, ***P < .001).
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Crypt Stem Cells
To examine whether UGT1 protein expression has an
impact on sustaining p53 activation through phosphoryla-
tion and the apoptosis markers in normal epithelial cells,
intestinal crypt cells from Ugt1DIEC and Ugt1F/F mice were
cultured and treated with different concentrations of eto-
poside (Figure 3). Targeted knockout of the Ugt1 locus in
Ugt1DIEC crypt cells led to a reduction in etoposide activated
phospho-p53 when compared with the same treatments
with Ugt1F/F crypt cells. We observed a dose-dependent
induction with a maximal response at 1 mM etoposide in
Ugt1F/F mice. A similar proﬁle was observed in Ugt1DIEC
mice, with a statistically signiﬁcant reduction at 1 mM.
Because induction of p53 in both Ugt1F/F and Ugt1DIEC mice
plateaued at 1 mM etoposide, statistical signiﬁcance was lost
at 10 mM.
Similar reduction patterns in apoptosis markers caspase
3 and p21 were also evident in Ugt1DIEC mice, but there wasFigure 3.Ugt1 knockout in intestinal crypt stem cells reduc
were cultured from Ugt1F/F and Ugt1DIEC adult mice. After passa
were cultured in 24-well plates. Four days later, cells were exp
concentrations of etoposide (ETO). Twenty four hours after ET
extracts were prepared and protein concentrations were quantita
Western blot analysis. Primary antibodies directed towards UGT
(Ser 15, Cell Signaling Technology), p21 (Cell Signaling Techno
used. Shown is a representation of multiple Western blots. Qua
analysis visualized by a ChemiDoc Touch Imaging System (Bio-R
expressed as “Fold of control”. Since induction patterns were be
mice, statistical comparisons were performed using two-way A
Prism. *P < .05.a lack of statistical signiﬁcance with caspase 3. The
phospho-p53 measured in these experiments is wild type
and not mutated p53, indicating that the impact of DNA
damage and phosphorylation of p53 activation is linked to
expression of the UGT1A proteins in normal epithelial cells.
In addition, because induction of p53 protein expression
does not result from transcriptional activation of p53 after
etoposide treatment (Supplementary Figure 2), expression
of the UGT1A proteins may interfere with post-translational
modulation of the phosphorylation of p53.Apoptosis Is Differentially Induced in Colons of
Ugt1DIEC and Ugt1F/FMice That Developed Acute
Colitis With Dextran Sodium Sulfate Treatment
As a well-established acute colitis model in mice, DSS
through oral administration induces inﬂammation and a
high level of intestinal epithelial cell (IEC) apoptosis in
colorectum.28 It is also appreciated that DSS-induced colonices p53 activation by etoposide. Intestinal crypt stem cells
ge, approximately 500–1000 cells per 50 ml of Matrigel per well
osed to fresh medium containing vehicle control or different
O exposure, cells were collected in RIPA buffer. Whole cell
ted. Thirty mg of protein were used for gel electrophoresis and
1A proteins (Santa Cruz Biotechnology), phosphorylated P53
logy), and active Caspase 3 (Cell Signaling Technology) were
ntitation of multiple Western blots was performed by density
ad Laboratories). Each band was normalized to a-tubulin and
ing compared between two groups, the Ugt1F/F and Ugt1DIEC
nova followed by the Benferroni correction using Graphpad
January 2016 UGT1A Expression Suppresses Tumor Growth 69apoptosis is dependent upon p53.29 With the recent devel-
opment of a mouse model targeting deletion of the Ugt1
locus in the IECs (Ugt1DIEC mice),14 we treated control
(Ugt1F/F) and Ugt1DIEC mice with 3% DSS for 5 days. The
induction of inﬂammation leads to a decrease in UGT1A
expression (Figure 4A), indicating that chemically induced
p53 activation is independent of UGT1A1 expression.
Compared with mice not given DSS, DSS-treated mice
exhibited signiﬁcant increases in the levels of p53, p21, Bax,
caspase-3, and caspase-9, accompanied by abundant
apoptotic cells in colon tissues detected by the TUNEL assay
(see Figure 4B).
When a comparison was made between Ugt1F/F and
Ugt1DIEC mice, DSS-induced p53 and p53-dependent target
gene products along with apoptotic biomarkers were
signiﬁcantly reduced in colons of Ugt1DIEC mice
(Supplementary Figure 3). By counting apoptotic epithelial
cells in colon, the TUNEL assay showed that apoptosisFigure 4. The impact of
DSS induced colitis on
p53 and apoptotic cells in
Ugt1DIEC mice. Ugt1DIEC
and Ugt1F/F mice were
treated with 3% DSS in
drinking water for 5 days to
induce acute colitis and
IEC apoptosis. After
another 5 days recovery
with regular water, colon
tissues were collected. (A)
Expression of UGT1A, p53,
p21, Bax, caspase-9, and
caspase-3 detected by
Western blot anaylsis.
GAPDH was used as a
loading control. Quantita-
tion of each Western
blot is presented in
Supplementary Figure 3.
(B) TUNEL staining of co-
lons from untreated mice
or DSS-treated mice (100X
Magniﬁcation). At least four
mice were analyzed in
each group and the
experiment was repeated
twice. (C) Quantitation of
the number of TUNEL
positive cells in DSS-
treated mice.occurred widely in both differentiated cells on the surface
plateau and cells in the crypt proliferative zones in Ugt1F/F
mice. However, DSS-treated Ugt1DIEC mice displayed a 38%
decrease in the number of apoptotic cells (Figure 4B and C),
indicating the reduction of p53-dependent apoptosis in the
absence of Ugt1a gene expression.
It is interesting to note that although DSS-induced acute
colitis is believed to be through inﬂammatory responses by
exposing innate immune cells in the lamina propria to
bacteria,30 we found that the extent of colonic inﬂammation
was not correlated to the level of IEC apoptosis between
DSS-treated Ugt1DIEC and Ugt1F/F mice. When Ugt1F/F mice
were treated with DSS, apoptosis in the IEC was accompa-
nied by severe inﬂammation and immune activation as the
colitis scores and the levels of proinﬂammatory markers,
such as tumor necrosis factor-a (TNF-a), interleukin-1b
(IL-1b), IL-6, and IL-8, were increased in colon tissues
(Supplementary Figure 4). Yet DSS-treated Ugt1DIEC mice,
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colitis scores and expression levels of the proinﬂammatory
cytokines TNFa, IL-1b, IL-6, and IL-8 in colon tissues. Colon
sections also showed similar morphologic features and ulcer
numbers in response to DSS treatment, as evidenced by
H&E staining (Supplementary Figure 4C and D), indicating
no signiﬁcant differences in inﬂammatory responses be-
tween Ugt1DIEC and Ugt1F/F mice. These data suggest that
Ugt1 knockout in the IEC did not inﬂuence DSS-induced
colon inﬂammation, and the alteration of apoptosis levels
may be largely mediated through p53-dependent signaling.Increased Colorectal Tumorigenesis in Ugt1DIEC
Mice With Azoxymethane Plus Dextran Sodium
Sulfate Treatment
Inactivation of p53 and decreased levels of apoptosis
have been associated with a higher risk of tissue neo-
plastic transformation. In particular, loss of p53 has
been linked to enhancing the incidence and multiplicity ofcolitis-associated neoplasia.31,32 Because DSS-induced p53
was diminished in colons of Ugt1DIEC mice, we further
examined the impact of Ugt1 deletion on CRC formation.
To initiate colon tumorigenesis, Ugt1F/F and Ugt1DIEC
mice were injected with a single dose of AOM (10 mg/kg), a
procarcinogen that induces DNA adduct formation after its
metabolic activation by CYP2E1.33 Subsequently, mice were
treated with three cycles of 2% DSS administration in
drinking water to induce colitis (Figure 5A).34 After 9 weeks
of treatment, both groups of mice, regardless of genotype,
developed colorectal tumors, which were mostly located in
the middle to distal colon sections (see Figure 5B). Strikingly,
Ugt1DIEC mice had a greater tumor number and larger tumor
size than Ugt1F/F mice in response to AOM and DSS treat-
ment. The number of detectable tumors was 62% higher in
Ugt1DIEC mice than in control Ugt1F/F mice (see Figure 5B
and D). In addition, approximately 15% of the tumors in the
Ugt1DIEC mice were >3 mm in diameter whereas none of the
Ugt1F/F mice developed tumors >3 mm (see Figure 5E).
When we performed histologic examinations, we found thatFigure 5. AOM plus DSS
treatment causes an
increased incidence and
increased size of tumors
in the colorectum of
Ugt1DIEC mice compared
to Ugt1F/F mice. (A) A
schematic schedule is
shown as the AOM plus
DSS feeding protocol.
Each rectangle represents
one week. (B) Photos of
colon tumors in Ugt1F/F
and Ugt1DIEC mice. (C)
Representative tumor
morphologies in colonic
sections by H&E staining
(50 and 200 magniﬁca-
tion). The black arrow in-
dicates the penetrating
adenoma. (D) Tumor inci-
dence and (E) size distri-
bution in Ugt1F/F and
Ugt1DIEC mice. At least
seven mice were analyzed
in each group, and results
are presented as mean ±
standard deviation (*P <
.05, **P < .01, ***P < .001).
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ﬂammatory cell inﬁltration (see Figure 5C).
Western blot analysis showed that AOM plus DSS treat-
ment led to a reduction in UGT1A expression in colonic
tumor tissues of Ugt1F/F mice, a phenomenon previously
observed in tumor tissue. Treatment with DSS after AOM
initiation led to induced p53 and p21 in the control Ugt1F/F
mice yet was abolished in the Ugt1DIEC mice (Figure 6A).
These results were similar to what we observed in mice
treated with one cycle of DSS alone, although there was no
difference in the expression levels of Bax and cleaved
caspase-3 between Ugt1F/F and Ugt1DIEC mice (see
Figure 6A). Quantitation of these Western blots is presented
in Supplementary Figure 5.
The TUNEL assay showed that Ugt1F/F and Ugt1DIEC mice
appeared to exhibit a similar level of apoptosis (see Figure 6B
and C). These data suggest that UGT1A proteins are an
important factor in determining p53 levels after initial acti-
vation and protecting IECs from tumorigenesis. However, the
p53-dependent signaling may play a lesser role in controlling
apoptosis during the late stage of tumor development.Figure 6. Protein expres-
sion of p53 and p53-
dependent genes and
detection of apoptosis in
the colorectum of Ugt1F/F
and Ugt1DIEC mice with
colorectal neoplasia after
AOM and DSS treatment.
Colorectum tissues from
AOM plus DSS-treated
Ugt1DIEC and Ugt1F/F mice
were collected and
analyzed. (A) Expression
levels of UGT1A, p53, p21,
Bax, and cleaved caspase-
3 were examined by
Western blot analysis with
GAPDH as a loading con-
trol. Quantitation of the
Western blots is shown in
Supplementary Figure 5.
(B) TUNEL staining of co-
lon sections (100 magni-
ﬁcation). (C) Quantiﬁcation
of the number of TUNEL
positive cells.Endoplasmic Reticulum Stress Is Involved in the
Down-Regulation of p53 Caused by
UGT1A Knockdown
Enzymes localized in the endoplasmic reticulum (ER)
play a vital role in maintaining ER homeostasis in response
to a variety of challenges. Recent studies have indicated that
there may be regulatory links between drug-transforming
enzymes and ER stress responding to xenobiotic stimuli.35
It is also known that ER stress plays a role in accelerating
p53 degradation and inhibiting cell apoptosis.36,37 With the
known and important association between p53 and ER
stress, we elected to explore the involvement of ER stress in
UGT1A-dependent p53 regulation by examining ER stress
marker genes, including GRP78, GRP94, spliced XBP1, ATF4,
by qRT-PCR (Figure 7).
In both intestinal HT29 and LS180 cell lines and the
Ugt1DIEC mouse model, we found that actinomycin D, eto-
poside, and DSS, acting as ER stress-inducing agents,
induced gene expression of all of the ER stress markers that
we examined in addition to activating p53 induction. The
knockdown of the Ugt1a genes further potentiated ER
Figure 7. Loss of UGT1A potentiates ER stress induced by actinomycin D, etoposide, or DSS treatment. LS180 and
HT29 cells were pretreated with UGT1A siRNA or nonspeciﬁc siRNA for 48 hours and then incubated with actinomycin D
(ActD, 40 nM) or etoposide (Eto, 80 mM) for 36 hours. Ugt1DIEC and Ugt1F/F mice were treated with 3% DSS in drinking water
and colon tissues were collected. Expression of ER stress-responsive genes was quantitated by Q-PCR.
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stress markers (see Figure 7). These results indicate that
UGT1A expression may have a role in maintaining ER ho-
meostasis, particularly when the cells are under stress, and
that increased levels of ER stress resulting from UGT1A
knockdown may have a direct impact on expression and
function of p53 after p53 activation has taken place.Discussion
In healthy cells and organs, low p53 levels are
maintained by Mdm2 through a negative-feedbackloop.38 When cells sense stress signals, p53 can accu-
mulate and transcriptionally regulate genes to control
cell cycle and cell death. For example, p53 accumulation
can lead to cell cycle arrest by inducing expression of
p21, a cyclin-dependent kinase inhibitor. Accumulation
of p53 is also required for the occurrence of apoptosis
by inducing the expression of various proapoptotic
genes, such as Bax, caspase-3, and caspase-9.39 The
maintenance of the growth-inhibitory responses by
elevated levels of p53 is essential for cells to adapt to
the stress and accounts for p53-dependent antitumori-
genesis activity.
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under stress, induced by actinomycin D or etoposide,
UGT1A expression is required for the maintenance of
elevated levels of p53, which determines whether the cell
undergoes apoptosis and/or cell arrest. The absence of
UGT1A expression, through siRNA silencing, disturbs this
adaptive mechanism initiated by p53, leading to inhibition
of up-regulation of p53-dependent target genes, such as
proapoptotic genes caspase-3 and caspase-9, and to subse-
quent inhibition of apoptosis.
When an in vivo study was performed using DSS to
induce colitis in colon tissue, we observed p53 accumulationFigure 8. Aworkingmodel
that demonstrates control
of apoptosis and tumori-
genesis by UGT1A pro-
teins through regulation of
p53. In this model, we are
showing that p53 when
activated can induce
apoptosis and repress tu-
mor formation. After p53
activation by cellular or
chemical stress the pres-
ence of UGT1A proteins in
the endoplasmic reticulum
(ER) is required to sustain
and maintain p53 levels.
Knockdown of the UGT1
locus and the resulting
UGT1A proteins increases
ER stress leading to inhi-
bition of p53 activation/
elevation and subsequent
reduction in apoptosis and
tumor suppression.accompanied by a higher incidence of apoptosis. However,
when colitis is induced in mice deﬁcient in intestinal Ugt1a
gene expression, p53 accumulation is reduced and apoptosis
is inhibited. More importantly, when challenged with AOM
in combination with DSS, Ugt1DIEC mice exhibited a large
increase in tumor multiplicity and size compared with
control mice, indicating that activated p53 requires UGT1A
to maintain and exert its function in protecting cells from
tumorigenesis.
Down-regulation of UGT1A proteins occurs in solid tu-
mors when compared with the surrounding healthy
tissue.13–17 UGT down-regulation is also observed in
74 Liu et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 1inﬂammation-related diseased organs (e.g., intestine and
liver).40,41 Possible contributing factors that cause a
decrease in UGT1A gene expression in tumor and/or
diseased tissues have been reported to be epigenetic mod-
ulation, inﬂammatory factor-mediated inhibition, and
reduction of xenobiotic nuclear receptor expression.42
These studies emphasize that the down-regulation of
UGT1A genes is the result of the disease state in various
tissues and its impact on the detoxiﬁcation capacity of xe-
nobiotics, especially cancer drugs.
By comparison, we report that under stress, UGT1A
expression is a key factor that determines p53-dependent
cell cycle regulation and cell death and has a direct impact
on antitumorigenesis in colon tissue. Our result is of sig-
niﬁcance because it indicates that UGT1A proteins play a
role in cell protection through both chemical detoxiﬁcation
and—reported here for the ﬁrst time—maintenance of p53
activation in response to cellular stress. Reduced expression
of Ugt1a genes in the diseased colon tissue not only leads to
lower detoxiﬁcation capacity for their substrates, it also
exacerbates the disease condition by inhibiting p53-
dependent proapoptosis and/or cell arrest. This ﬁnding
may explain that the patients with inﬂammatory diseases
often have a higher risk of developing cancer43 because
lower UGT1A expression in the disease condition and sub-
sequent inactivation of the p53-dependent antitumori-
genesis pathway may be one of the contributing
mechanisms that account for the tumorigenic action. We
speculate that UGT1A activity may have a global effect on
maintaining p53 activation in various tissues when cells
encounter stress.
A central mechanism linking UGT1A expression and
sustaining activated p53 is unclear. We explored the
involvement of ER stress because it has been shown to
induce p53 cytoplasmic localization and degradation, pre-
venting p53-dependent apoptosis.36,37,44 ER stress is acti-
vated by physiologic conditions such as nutrient deprivation
or by xenobiotic and drug toxicities, leading to the accu-
mulation of unfolded proteins.45 The generation of unfolded
proteins stimulates an adaptive process, the unfolded pro-
tein response that leads to the activation of cellular ma-
chinery needed to repair the unfolded proteins.
Interestingly, recent studies indicate that there may be a
regulatory link between ER stress and biotransformation
enzymes: in vivo and in vitro experiments revealed that
overexpression or induction of CYPs can cause up-
regulation of the unfolded protein response.35 Because the
UGTs play a key role in xenobiotic metabolism and cellular
protection against toxicants, regulatory links controlling the
UGTs, p53, and ER stress may be an important network
during tissue neoplastic transformation.
We have observed that when colon cells are under
stress, p53 elevation is accompanied by perturbation of ER
homeostasis reﬂected by induction of ER-resident proteins.
Loss of UGT1A expression, particularly in DSS-treated
Ugt1DIEC mice, potentiates ER stress while dramatically
down-regulating the expression of p53. Alongside our re-
sults, previous studies have shown that ER stress promotes
p53 degradation in the cytoplasm by the ER-residentubiquitin ligase synoviolin.44 We can speculate that since
the UGT1A proteins and Synoviolin are located in the ER,
further investigation as to the novel role of the UGT1A
proteins in down-regulating synoviolin-generated ubiquitin
ligase targeting of p53 would shed light on how the absence
of UGT1A proteins could potentially lead to ER-associated
p53 degradation.
The UGTs exist as dimers in the ER and form both
momomeric and heterodimer complexes.46 The UGTs have
also been shown to dimerize with other ER-based proteins,
such as the cytochrome P450s.47–50 Because knockout of the
UGT1A proteins during stress in colon tissue leads to de-
creases in p53 abundance, the possibility exists that the
UGTs may interact through protein–protein interactions and
play an important role in controlling activation of ER-
localized synoviolin, which controls the levels of phos-
phorylated cytoplasmic p53. Our working model of this
study is illustrated in Figure 8.
To achieve proper function, p53 is tightly regulated by
means of post-translational modiﬁcations, cofactor binding,
and subcellular localization. For example, a classic p53
regulator Mdm2, an E3 ubiquitin ligase, inactivates p53 by
accelerating its nuclear export and degradation when cells
are under a basal condition.38 Our ﬁndings suggest that
UGT1A genes act as an important p53 regulator by main-
taining p53 elevation after cellular stress. Studies have
shown that when p53 is activated, post-transcriptional
modiﬁcations such as p53 phosphorylation and acetylation
can protect p53 from degradation.38 This statement is
consistent with our ﬁnding that p53 protein phosphoryla-
tion expression was down-regulated with unchanged tran-
scriptional activity (Supplementary Figure 5), as we
observed a loss of UGT1A expression after actinomycin D,
etoposide, and DSS treatment.
As a tumor suppressor gene, p53 is involved in tumori-
genesis through one of three mechanisms: (1) Complete loss
of wild-type p53 leading to dysregulation of cell cycle and
cell death; (2) suppression of normal function of the wild
type p53 by mutant p53; and (3) pro-oncogenic properties
exerted by the mutant p53.51 In our study, the tumorigenic
action elicited by loss of UGT1A expression is most likely
through inhibition of wild-type p53. Our results imply that,
at least in certain tissues and conditions, UGT1A levels may
be a reliable clinical marker that can predict the tumorigenic
potential of these tissues. In summary, this study provides
compelling evidence that UGT1A expression is essential to
maintain p53 accumulation, promoting apoptosis and pre-
venting cells from undergoing tumorigenesis in the disease
state.
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Supplementary Figure 1. Quantitation of Western blots after UGT1A silencing in LS180 and HT29 colon epithelial cells.
Western blots from actinomycin D and etoposide treated cells from LS180 (Figure 1B) and HT29 (Figure 1C) cells were
quantitated using imaging software from the BioRad ChemiDoc Touch Imaging System and plotted as Relative Signal Intensity
or t/c (target protein/internal reference protein-GAPDH). Statistically signiﬁcant differences in inducible p53 expression along
with p21, Bax, caspase 3 and caspase 9 expressions were demonstrated after knockdown of the Ugt1a locus in these cells.
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Supplementary Figure 1. (continued).
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Supplementary Figure 2. P53 gene expression analysis. Human HT29 and LS180 cells treated with actinomycin D or
etoposide after siRNA knockdown of the UGT1 locus were used to quantitate by real time PCR gene expression of the p53
gene. Similar quantitation was performed using intestinal RNA from Ugt1F/F and Ugt1DIEC mice after DSS treatment to induce
intestinal inﬂammation.
Supplementary Figure 3. Western blot quantitation after treatment with DSS. After treatment with DSS, colon tissue was
collected from Ugt1F/F and Ugt1DIEC mice and Western blots performed on total cell extracts (Figure 4). Quantitation of the
proteins were conducted and plotted as relative values from three separate experiments.
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Supplementary Figure 4. No marked changes in the severity of ulcer or inﬂammatory gene expression in colon tissues
between Ugt1DIEC and Ugt1F/F mice after DSS treatment. Colon tissues from 3% DSS-treated or untreated Ugt1DIEC and
Ugt1F/F mice were used to prepare total samples of total RNA. (A) Expression of inﬂammatory genes was quantitated by real-
time PCR, and normalized to the level of cyclophilin mRNA. (B) Colitis score quantiﬁed by stool occult blood, rectal prolapse,
and diarrhea. Results are presented as mean ± standard deviation of at least four mice. (C) Quantiﬁcation of the number of
ulcers by analyzing H&E-stained sections. (D) Colon ulcers are shown by H&E staining (200 magniﬁcation).
Supplementary Figure 5. Western blot quantitation after AOM (A) and DSS (D) treatment as outlined in Figure 6A.
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IL-8 5ʹ- ATGCCCTCTATTCTGCCAGAT-3ʹ 5ʹ-GTGCTCCGGTTGTATAAGATGAC-3ʹ
Human P53 5ʹ-GAGGTTGGCTCTGACTGTACC-3ʹ 5ʹ-TCCGTCCCAGTAGATTACCAC-3ʹ
Human ATF-4 5ʹ-TTAAGCCATGGCGCTTCTCA-3ʹ 5ʹ-GGTCGAAGGGGGACATCAAG-3ʹ
Human sxbp-1 5ʹ-TTAAGACAGCGCTTGGGGAT-3ʹ 5ʹ-GCAGAGGTGCACGTAGTCTGA-3ʹ
Human GRP-78 5ʹ-CCCGTGGCATAAACCCAGAT-3ʹ 5ʹ-TGGTAGGCACCACTGTGTTC-3ʹ
Human GRP-94 5ʹ-GCCAGTTTGGTGTCGGTTTC-3ʹ 5ʹ-GGGTAATTGTCGTTCCCCGT-3ʹ
Human actin 5ʹ-GGCGGCACCACCATGTACCCT-3ʹ 5ʹ-AGGGGCCGGACTCGTCATACT-3ʹ
Mouse p53 5ʹ-CCAAACTGCTAGCTCCCATCA-3ʹ 5ʹ-GGCCCCACTTTCTTGACCAT-3ʹ
Mouse ATF-4 5ʹ-AATTCGTCAACGAGCGATCC-3ʹ 5ʹ-CTGCTGCCTCTAATACGCCA-3ʹ
Mouse sxbp-1 5ʹ-ATCGCAGGGAGGGTCATTTG-3ʹ 5ʹ-TGGGGTCAAGAGGGTCAGAA-3ʹ
Mouse GRP-78 5ʹ-CGATACTGGCCGAGACAACA-3ʹ 5ʹ-GGAGGAGACACGAAGCAGAC-3ʹ
Mouse GRP-94 5ʹ-ACCGAAAAGGACTTGCGACT-3ʹ 5ʹ-AGCCTTCTCGGCTTTTACCC-3ʹ
Mouse cyclophilin 5ʹ-CAGACGCCACTGTCGCTTT-3ʹ 5ʹ-TGTCTTTGGAACTTTGTCTGCAA-3ʹ
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